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Alternative methods for identifying endocrine disruptors and reproductive toxicants

Ideology Masquerading as Science: The Case of Endocrine
Disrupter Screening Programmes
Troy Seidle
People for the Ethical Treatment of Animals, 501 Front Street, Norfolk, VA 23510, USA
E-mail: troys@peta.org
Summary — The global move to develop novel testing methods and strategies to identify suspected
endocrine disrupting chemicals offers a unique opportunity to move away from traditional animal testing
paradigms in this new area of regulatory concern. Regrettably, the programmes under development, both
in the USA and internationally through the OECD, have thus far failed to consider in vitro and other nonanimal test methods as more than “pre-screening” or “priority-setting” tools in a larger, animal-based testing strategy. Validation efforts to date have focused almost exclusively on the modification of existing
animal tests to detect “endocrine effects”, with no demonstrable effort to promote international coordination or support for the development and validation of relevant non-animal test systems. The current orientation in these programmes reflects ideological, rather than scientific, imperatives, and undermines the
commitments of both the US government and the OECD with respect to the Three Rs and the minimisation of animal testing.
Key words: endocrine disrupter testing, non-animal test methods.

Introduction
The term “endocrine disrupter” entered the public
lexicon in 1996, with the publication of the book,
Our Stolen Future: Are We Threatening Our
Fertility, Intelligence and Survival? — A Scientific
Detective Story (1). The book, co-authored by environmental activist, and later WWF senior scientist,
Theo Colborn, sought to implicate synthetic chemicals as the root of everything from reproductive
anomalies in wildlife to neurodevelopmental
deficits in human children.
Although Our Stolen Future received considerable hype in the mainstream media, scientific publications were less enthusiastic about the book or
the scientific rigor of its authors. For example, a
Scientific American editorial (2) concluded: “The
book is not scientific. . . . The authors present a
very selective segment of the data that have been
gathered about chemicals that might affect hormonal functions. They carefully avoid evidence
and interpretations that are not in accord with
their thinking”. Similarly, a review published in
the journal, Science (3), noted, “. . . the authors’
lack of discrimination between anecdotal reports
and meticulous scientific studies. One paragraph
describes a carefully crafted study, the next
indulges in wild speculation. . . . This lack of selectivity diminishes the impact of the book because it
raises serious questions about the scientific judgment of the authors”.
Just when the media hype surrounding Our
Stolen Future began to fade, investigators at Tulane
University published a study reporting that combinations of polychlorinated biphenols (PCBs) and

pesticides were up to 1000 times more potent as
endocrine disruptors than the individual chemicals
alone (4). According to former US Environmental
Protection Agency (EPA) administrator, Carol
Browner (5): “The new study is the strongest evidence to date that combinations of oestrogenic chemicals may be potent enough to significantly increase
the risk of breast cancer, prostate cancer, birth
defects and other major health concerns”. Similar
views were expressed by then EPA Assistant
Administrator for Prevention, Pesticides and Toxic
Substances, Lynn Goldman, who described the
Tulane study (6) as, “the best case of synergy
between chemicals at low doses that I have ever
seen”, and further, that “I just can’t remember a
time where I’ve seen data so persuasive. . . . The
results are very clean-looking” (see 5).

Discussion
The Tulane study received a great deal of publicity,
which played a considerable role in driving the US
Congress to pass the Food Quality Protection Act of
1996 (7), which requires the EPA to “develop a
screening programme . . . to determine whether certain substances may have an effect in humans that
is similar to an effect produced by a naturally occurring oestrogen, or such other endocrine effect as the
Administrator may designate”. However, a mere six
months after its publication, the Tulane study
began to unravel. Scientists from around the world
began to report that they could not reproduce the
study’s results (8, 9). By August 1997, the study’s
lead author had retracted the study from publica-
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tion (10). Subsequently, the US Office of Research
Integrity (ORI) concluded that the study’s authors,
“committed scientific misconduct by intentionally
falsifying the research results published in the journal Science and by providing falsified and fabricated
materials to investigating officials” (11). ORI also
found that, “there is no original data or other corroborating evidence to support the research results
and conclusions reported in the Science paper as
a whole”. The penalty imposed was a 5-year ban
from receiving US federal grants.
Quite apart from the controversy surrounding
the Tulane study, a number of eminent scientists
began to question the relevance and timeliness of a
large-scale programme to test chemicals for suspected “endocrine disrupting” effects. The US
National Research Council report, Hormonally
Active Agents in the Environment (12), noted:
“There are important differences among species
and between adult and developing organisms in
responses to endocrine disrupters. These differences could have important implications when
assessing toxicity studies or extrapolating data
from one species to another”. Similarly, an editorial
by Ashby & Elliott (13) in the journal Regulatory
Toxicology and Pharmacology, documented a litany
of examples of the difficulties encountered in
attempting to reproduce observations reported in
studies of endocrine disruption, noting: “In some
cases, effects will not reproduce because they were
not real”. Even members of the environmental community have questioned the foundation of the
Endocrine Disruptor Screening Program (EDSP;
14), noting that endocrine disruption is becoming
the “industry endpoint of choice”, because such a
classification will place a chemical into a “bottomless pit of study” in a “regulatory safety zone”.
Perhaps most telling, however, are comments made
by Dr Ernest McConnell, then chair of the EPA’s
Scientific Advisory Panel/Science Advisory Board
joint subcommittee on endocrine disrupters, that
“. . . there was an undercurrent through the whole
discussion that the EPA programme was ahead of
the science. . . . This may not be the best use of our
nation’s resources”.
Remarkably, the retraction of the Tulane study
and the sage words of caution from respected scientific authorities were barely a bump in the road to
the mass testing of chemicals for suspected
“endocrine disrupting” effects, which suggests that
politics –– as opposed to science –– is the major
driver behind endocrine disrupter testing programmes.
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Advisory Committee (EDSTAC), which included
representation from all major stakeholder groups,
with the exception of the animal protection community (15). Perhaps not surprisingly, the Three Rs
of reduction, refinement and replacement were also
not considered or reflected in EDSTAC’s report and
recommendations to the EPA (16). In fact, many of
EDSTAC’s “screening criteria” (17) are antithetical
to the Three Rs, including the promotion of “redundancy among endpoints across assays”, and the relegation of in vitro methods to mere “priority
setting” status by establishing, a priori, that “the
results of in vivo assays should be given greater
weight than similar results in vitro”. EDSTAC also
failed to appreciate the importance of proper validation, by suggesting that in vivo methods are “generally well accepted in toxicity testing”, which
erroneously equates a history of use with validation
(18).
Activity in the USA is also being mirrored internationally. In 1996, the OECD established a Task
Force on Endocrine Disrupter Testing and
Assessment (EDTA), with representation from both
national governments and non-governmental entities. From the EDTA emerged two Validation
Management Groups (VMGs), each with a mandate
to oversee the development and validation of exclusively in vivo tests, for mammalian and ecotoxicological effects, respectively. It was only in June of
2002 that in vitro and other non-animal approaches
began to be given serious consideration or prominence in the OECD’s proposed “toolbox” of screening and testing methods. This modest, but
important, shift culminated with a proposal to
establish a third VMG specific to non-animal
screening and testing methods.
Although there now appears to be some visible
movement toward a more holistic application of the
Three Rs –– including Japan’s leadership in the
development of high-throughput screening systems
(J. Kanno, personal communication), the EPA’s work
to develop a cell-line model for steroidogenesis/aromatase inhibition (19), an in vitro amphibian gene
array for ecotoxicity screening (G. Timm, personal
communication, 12.5.01), and recent movement
toward a “Technology Challenge” funding programme (20) –– there are still numerous areas in
which the Three Rs are being applied inadequately, if
at all.
Failure to adequately apply the Three Rs

Questionable guidance

There is currently an unconscionable amount of
redundancy in the assays being developed in both
the USA and internationally. For example:

The EDSP in the USA is being structured according
to the recommendations of the EPA’s former
Endocrine Disrupter Screening and Testing

1. The EPA has proposed to develop and validate
several separate iterations of a pubertal assay
(21).

Endocrine disruptor screening programmes

2. Proposed testing frameworks, both in the USA
and internationally, include five redundant and
highly animal-intensive chronic/multi-generational reproduction studies in multiple taxonomic groups (18, 22).
3. There are several examples where a multiplicity
of assays is being developed for the same endpoint. These include the amphibian metamorphosis and pubertal assays to assess thyroid
disruption, the uterotrophic and pubertal
female assays for oestrogen agonism/antagonism, and the Hershberger and pubertal male
assays for androgen agonism/antagonism (23).
Had the EPA stuck to the letter of the law, i.e. “to
determine whether certain substances may have an
effect in humans that is similar to an effect produced by a naturally occurring oestrogen” (7), animal testing could be vastly reduced. For example,
screening only for human health effects, as was the
intent of the Food Quality Protection Act, would preclude the need to examine the various ecotoxicity
endpoints. This would eliminate the amphibian
metamorphosis and fish screening assays (vitellogenin induction and gonadal histopathology) from
the EPA’s proposed Tier 1, and, more importantly,
from a reduction perspective, four of the five animalintensive chronic/multi-generational reproduction
studies from Tier 2 (22). Compelling ethical and
practical considerations favour such an approach.
The final report of the EPA’s joint Scientific
Advisory Panel and Science Advisory Board
(SAP/SAB) subcommittee on endocrine disrupters
(24) states the matter very clearly: “We are concerned about the large number of animals that
would be needed by the EDSTAC programme. The
agency has an obligation to conserve all resources in
developing new testing protocols, and the use of animals in such tests poses both ethical and practical
problems. The subcommittee recommends . . . minimising the number of animals needed for testing”.
From a strictly pragmatic perspective, there are
very few examples of substances being subject to
more-stringent regulation on the basis of ecological
effects in the absence of adverse human health
effects (A. Rispin, personal communication). It is
therefore not at all clear that the results of wildlifepoisoning studies will have any appreciable impact
on the manner in which chemicals are regulated, or
otherwise the manner in which regulatory agencies
fulfil their mandate to protect wildlife and the environment.
At this point, it should go without saying that
regulatory agencies could do much more from a
reduction perspective. Both individual toxicologists
and companies like Proctor & Gamble have proposed that mechanistic/Tier 1 screening can and
should be carried out by using strictly in vitro
methods (25, 26). To date, this option has been
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given inadequate consideration, both in the USA
and internationally.
Protocol refinement is also being overlooked, as
evidenced by the overemphasis on using mature
animals in the validation of the uterotrophic and
Hershberger assays (27) –– which results in animals
being subjected to unnecessary and invasive surgical sterilisation.
Promising replacement options should be given
greater attention. Examples include the study of
vitellogenin induction in vitro rather than in fish
(28–30), the use of in vitro metabolism and biokinetic studies to enhance receptor-binding assays
(31), which could potentially serve as a replacement
for the uterotrophic and Hershberger assays, and
the assessment of adverse effects on the thyroid
through in vitro studies of thyroid biochemistry and
cell morphology (32–34).

Conclusions
Failure by regulatory agencies to fully embrace and
apply the Three Rs at every stage in their chemical
testing and assessment strategies will result in a
magnitude of animal suffering and death that is as
unconscionable as it is avoidable. The mass animal
testing frameworks proposed to date did not fall from
the sky on stone tablets –– they merely reflect the
perspective of a select group of stakeholders at one
point in time. They should not be adhered to in a rigid
and inflexible manner, and must continually evolve
to reflect both scientific and ethical advancements.
The animal protection community is committed
to working constructively with regulatory agencies
and other stakeholders to further this end.
However, it will take much more than reiterating
one’s commitment to animal welfare and the Three
Rs to get the job done. The time for talk is over.
What is needed now, is action.
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